Biomarin Pharmaceutical (BMRN) Cash & Equivalents (2009 - 2026)

Biomarin Pharmaceutical has disclosed Cash & Equivalents across 18 years of filings, most recently posting $2.2 billion for Q1 2026.

• Quarterly Cash & Equivalents rose 111.9% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 111.9% YoY) and the FY2025 annual result came in at $1.3 billion, up 39.12% from the prior year.
• Cash & Equivalents improved to $2.2 billion in Q1 2026, from $1.3 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $2.2 billion in Q1 2026 and troughed at $580.1 million in Q1 2023.
• A 5-year average of $935.9 million and a median of $761.5 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents dropped 14.0% — and 2026, when it jumped 111.9%.
• Tracing BMRN's Cash & Equivalents over 5 years: stood at $724.5 million in 2022, then grew by 4.22% to $755.1 million in 2023, then increased by 24.86% to $942.8 million in 2024, then soared by 39.12% to $1.3 billion in 2025, then soared by 69.43% to $2.2 billion in 2026.
• Business Quant data shows BMRN's Cash & Equivalents at $2.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.